» Articles » PMID: 37813626

In-silico and Structure-based Assessment to Evaluate Pathogenicity of Missense Mutations Associated with Non-small Cell Lung Cancer Identified in the Eph-ephrin Class of Proteins

Overview
Journal Genomics Inform
Publisher Biomed Central
Specialty Biology
Date 2023 Oct 9
PMID 37813626
Authors
Affiliations
Soon will be listed here.
Abstract

Ephs belong to the largest family of receptor tyrosine kinase and are highly conserved both sequentially and structurally. The structural organization of Eph is similar to other receptor tyrosine kinases; constituting the extracellular ligand binding domain, a fibronectin domain followed by intracellular juxtamembrane kinase, and SAM domain. Eph binds to respective ephrin ligand, through the ligand binding domain and forms a tetrameric complex to activate the kinase domain. Eph-ephrin regulates many downstream pathways that lead to physiological events such as cell migration, proliferation, and growth. Therefore, considering the importance of Eph-ephrin class of protein in tumorigenesis, 7,620 clinically reported missense mutations belonging to the class of variables of unknown significance were retrieved from cBioPortal and evaluated for pathogenicity. Thirty-two mutations predicted to be pathogenic using SIFT, Polyphen-2, PROVEAN, SNPs&GO, PMut, iSTABLE, and PremPS in-silico tools were found located either in critical functional regions or encompassing interactions at the binding interface of Eph-ephrin. However, seven were reported in nonsmall cell lung cancer (NSCLC). Considering the relevance of receptor tyrosine kinases and Eph in NSCLC, these seven mutations were assessed for change in the folding pattern using molecular dynamic simulation. Structural alterations, stability, flexibility, compactness, and solvent-exposed area was observed in EphA3 Trp790Cys, EphA7 Leu749Phe, EphB1 Gly685Cys, EphB4 Val748Ala, and Ephrin A2 Trp112Cys. Hence, it can be concluded that the evaluated mutations have potential to alter the folding pattern and thus can be further validated by in-vitro, structural and in-vivo studies for clinical management.

Citing Articles

Therapeutic advances of targeting receptor tyrosine kinases in cancer.

Tomuleasa C, Tigu A, Munteanu R, Moldovan C, Kegyes D, Onaciu A Signal Transduct Target Ther. 2024; 9(1):201.

PMID: 39138146 PMC: 11323831. DOI: 10.1038/s41392-024-01899-w.


Cancer-Related Mutations in the Sam Domains of EphA2 Receptor and Ship2 Lipid Phosphatase: A Computational Study.

Vincenzi M, Mercurio F, Autiero I, Leone M Molecules. 2024; 29(5).

PMID: 38474536 PMC: 10935306. DOI: 10.3390/molecules29051024.

References
1.
Chen Z, Liu Z, Zhang M, Huang W, Li Z, Wang S . EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2-mediated MAPK pathway activation in gastric cancer cells and avatar mice. Int J Cancer. 2019; 145(9):2440-2449. DOI: 10.1002/ijc.32313. View

2.
Chikhale V, Goswami N, Khan M, Borah P, Varma A . Evaluation of Pathogenicity and Structural Alterations for the Mutations Identified in the Conserved Region of the C-Terminal Kinase Domain of Human-Ribosomal S6 Kinase 1. ACS Omega. 2023; 8(18):16273-16283. PMC: 10173430. DOI: 10.1021/acsomega.3c00722. View

3.
Giaginis C, Tsoukalas N, Bournakis E, Alexandrou P, Kavantzas N, Patsouris E . Ephrin (Eph) receptor A1, A4, A5 and A7 expression in human non-small cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival. BMC Clin Pathol. 2014; 14(1):8. PMC: 4234387. DOI: 10.1186/1472-6890-14-8. View

4.
Li R, Sun Y, Jiang A, Wu Y, Li C, Jin M . Knockdown of ephrin receptor A7 suppresses the proliferation and metastasis of A549 human lung cancer cells. Mol Med Rep. 2016; 13(4):3190-6. DOI: 10.3892/mmr.2016.4904. View

5.
Modi V, Dunbrack Jr R . Defining a new nomenclature for the structures of active and inactive kinases. Proc Natl Acad Sci U S A. 2019; 116(14):6818-6827. PMC: 6452665. DOI: 10.1073/pnas.1814279116. View